Year-End Report 22/23
September 2022 – August 2023, Diamyd Medical AB (publ), Fiscal year 2022/2023Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com September 1, 2022 – August 31, 2023 · Operating income: MSEK 19.6 (2.6), fourth quarter: MSEK 11.2 (1.2). The increase in operating income refers mainly to milestones related to a partnership agreement with JDRF · Net result: MSEK -100.2 (-103.5), fourth quarter: MSEK -21.6 (-36.7) ·